JPWO2021168197A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021168197A5 JPWO2021168197A5 JP2022549454A JP2022549454A JPWO2021168197A5 JP WO2021168197 A5 JPWO2021168197 A5 JP WO2021168197A5 JP 2022549454 A JP2022549454 A JP 2022549454A JP 2022549454 A JP2022549454 A JP 2022549454A JP WO2021168197 A5 JPWO2021168197 A5 JP WO2021168197A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- cycloalkyl
- compound according
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978635P | 2020-02-19 | 2020-02-19 | |
| US62/978,635 | 2020-02-19 | ||
| PCT/US2021/018710 WO2021168197A1 (en) | 2020-02-19 | 2021-02-19 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026016996A Division JP2026074171A (ja) | 2020-02-19 | 2026-02-04 | インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023514323A JP2023514323A (ja) | 2023-04-05 |
| JPWO2021168197A5 true JPWO2021168197A5 (https=) | 2024-02-27 |
| JP2023514323A5 JP2023514323A5 (https=) | 2024-02-27 |
| JP7815127B2 JP7815127B2 (ja) | 2026-02-17 |
Family
ID=74870905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549454A Active JP7815127B2 (ja) | 2020-02-19 | 2021-02-19 | インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12528814B2 (https=) |
| EP (1) | EP4107158A1 (https=) |
| JP (1) | JP7815127B2 (https=) |
| KR (1) | KR20220155295A (https=) |
| CN (1) | CN115335381A (https=) |
| AU (1) | AU2021224923A1 (https=) |
| CA (1) | CA3165009A1 (https=) |
| TW (1) | TW202140489A (https=) |
| WO (1) | WO2021168197A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US11739101B2 (en) | 2020-05-06 | 2023-08-29 | Nurix Therapeutics, Inc. | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof |
| FI4367118T3 (fi) * | 2021-08-18 | 2025-04-09 | Nurix Therapeutics Inc | Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö |
| EP4430052A1 (en) | 2021-11-10 | 2024-09-18 | Nurix Therapeutics, Inc. | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof |
| AU2022405474A1 (en) * | 2021-12-08 | 2024-07-18 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications |
| WO2023186069A1 (zh) * | 2022-03-31 | 2023-10-05 | 石药集团中奇制药技术（石家庄）有限公司 | 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途 |
| CN119630802A (zh) | 2022-04-12 | 2025-03-14 | 建新公司 | Irak4调节剂用于基因疗法的用途 |
| CN117164583A (zh) * | 2022-05-20 | 2023-12-05 | 斯迈旭(苏州)生物科技有限公司 | 一种靶向irak4蛋白降解的化合物及其应用 |
| KR20260005340A (ko) * | 2023-05-30 | 2026-01-09 | 상하이 후이룬 파마슈티컬 컴퍼니 리미티드 | 트리시클릭 화합물, 이의 제조 방법 및 적용 |
| CN120202200A (zh) * | 2023-06-01 | 2025-06-24 | 标新生物医药科技(上海)有限公司 | 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用 |
| WO2025036451A1 (zh) * | 2023-08-15 | 2025-02-20 | 潘普洛纳生物科技（深圳）有限公司 | 靶向irak蛋白抑制或降解的化合物及其应用 |
| WO2025126115A1 (en) | 2023-12-13 | 2025-06-19 | Beigene Switzerland Gmbh | Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use |
| WO2025149070A1 (zh) * | 2024-01-10 | 2025-07-17 | 甘李药业股份有限公司 | 一种新型靶向白细胞介素1受体关联激酶4(irak4)的蛋白降解嵌合体化合物的合成及其应用 |
| CN118406019B (zh) * | 2024-07-02 | 2024-09-20 | 苏州源起材料科技有限公司 | 一种噻唑化合物生物医药砌块的合成方法 |
| WO2026050190A1 (en) * | 2024-08-27 | 2026-03-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Smyd3 protacs for the treatment of hpv-negative squamous cell carcinoma |
| CN119119080A (zh) * | 2024-09-06 | 2024-12-13 | 上海信诺维生物医药有限公司 | 一种irak4的蛋白降解剂 |
| CN120757537B (zh) * | 2025-09-09 | 2026-01-06 | 广东省科学院动物研究所 | Protac降解剂及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7041298B2 (en) | 2000-09-08 | 2006-05-09 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7030112B2 (en) | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| CA2663091A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| CN104254533B (zh) * | 2012-01-13 | 2017-09-08 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 |
| US9464326B2 (en) | 2012-03-22 | 2016-10-11 | University Of Maryland, Baltimore | Total and phosphorylated IL-1 receptor-associated kinase-1 and IL-1 receptor-associated kinase-4 as a biomarker for cancer progression and chemotherapy resistance |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TW201718571A (zh) * | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| ES2822956T3 (es) * | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
| US10487329B2 (en) | 2015-10-29 | 2019-11-26 | Children's Hospital Medical Center | Methods and compositions for the treatment of head and neck cancer |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| EP3532164A4 (en) | 2016-10-28 | 2020-10-07 | Children's Hospital Medical Center | TREATMENT OF IRAQ ASSOCIATED DISEASES ACTIVATED |
| BR112019015484A2 (pt) | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| WO2018232288A1 (en) | 2017-06-16 | 2018-12-20 | Genentech, Inc. | Diagnostic and therapeutic methods for irak4-mediated disorders and conditions |
| US11065231B2 (en) * | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| WO2019103196A1 (ko) | 2017-11-24 | 2019-05-31 | 엘지전자 주식회사 | 무선 통신 시스템에서 빔을 리포팅하는 방법 및 장치 |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019160915A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| US20200038513A1 (en) | 2018-07-26 | 2020-02-06 | Arvinas Operations, Inc. | Modulators of fak proteolysis and associated methods of use |
| WO2020036830A1 (en) * | 2018-08-13 | 2020-02-20 | Gilead Sciences, Inc. | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors |
| TWI727392B (zh) | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4038066A1 (en) | 2019-10-01 | 2022-08-10 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| WO2021180103A1 (en) | 2020-03-11 | 2021-09-16 | Beigene, Ltd. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| MX2022016061A (es) | 2020-06-17 | 2023-02-02 | Kymera Therapeutics Inc | Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos. |
| WO2021255212A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Braf degraders |
| CA3217892A1 (en) | 2021-05-03 | 2022-11-10 | Joel Mcintosh | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
| FI4367118T3 (fi) | 2021-08-18 | 2025-04-09 | Nurix Therapeutics Inc | Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö |
-
2021
- 2021-02-19 EP EP21711431.3A patent/EP4107158A1/en active Pending
- 2021-02-19 CN CN202180015953.3A patent/CN115335381A/zh active Pending
- 2021-02-19 WO PCT/US2021/018710 patent/WO2021168197A1/en not_active Ceased
- 2021-02-19 CA CA3165009A patent/CA3165009A1/en active Pending
- 2021-02-19 KR KR1020227031406A patent/KR20220155295A/ko active Pending
- 2021-02-19 TW TW110105770A patent/TW202140489A/zh unknown
- 2021-02-19 JP JP2022549454A patent/JP7815127B2/ja active Active
- 2021-02-19 US US17/904,592 patent/US12528814B2/en active Active
- 2021-02-19 AU AU2021224923A patent/AU2021224923A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021168197A5 (https=) | ||
| JP6924765B2 (ja) | ステロイド誘導体ｆｘｒ作動薬 | |
| JP3014761B2 (ja) | タキサン誘導体の製造法 | |
| JP6639446B2 (ja) | 液晶混合物の製造方法 | |
| Schneider et al. | Palladium-and Copper-Catalyzed Stereocontrolled Direct C H Fluoroalkenylation of Heteroarenes using gem-Bromofluoroalkenes. | |
| RU2709496C1 (ru) | Способ получения аватромбопага | |
| JP2009500347A5 (https=) | ||
| JPH09502994A (ja) | １７−（３−ピリジル）ステロイドの合成 | |
| JP2024522290A (ja) | ナトリウムチャネルの置換テトラヒドロフラン調節因子の合成のためのプロセス | |
| ES2704951T3 (es) | Compuesto precursor de marcaje radioactivo y método para producir un compuesto marcado con flúor radioactivo utilizando el compuesto precursor | |
| AU2019266768B2 (en) | Method for producing oligonucleic acid compound | |
| US8148353B2 (en) | Polymorphs of fluticasone furoate and process for preparation thereof | |
| CA2871314A1 (en) | Process for preparation of 17-substituted steroids | |
| JPWO2019111853A1 (ja) | ジカルボン酸モノエステル体の製造方法、ジカルボン酸モノエステル塩および重合性液晶化合物の製造方法 | |
| CN111057070A (zh) | 一种巴洛沙韦关键中间体的合成方法 | |
| JPWO2023023255A5 (https=) | ||
| JPH1036355A (ja) | ４−アミノ−５−クロロ−６−（１−フルオロエチル）ピリミジン誘導体の製法 | |
| RU2650110C2 (ru) | Способы синтеза 2-амино-4,6-диметоксибензамида и других бензамидных соединений | |
| JPH07504425A (ja) | β−フェニルイソセリン及びその類似体の製造法 | |
| JPH08508281A (ja) | β−フェニルイソセリン誘導体の製造法 | |
| JPWO2021207550A5 (https=) | ||
| JPWO2021207530A5 (https=) | ||
| CN108047287B (zh) | 用于合成加利车霉素衍生物的中间体和方法 | |
| KR100868116B1 (ko) | 도세탁셀·모노프로필렌글라이콜 내포화합물 및 이의제조방법 | |
| JP2906228B2 (ja) | グルコピラノース誘導体の塩 |